Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RTW Biotech OpportunitiesLSE:RTW -1.15%40 3-1 Month Momentum % is 10.05% as of Aug. 15, 2026. GuruFocus rates LSE:RTW with a GF Score™ of 40/100. The stock has 2 warning signs investors should review. Among 1,627 Asset Management companies, RTW Biotech Opportunities ranks better than 91.15% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-15), RTW Biotech Opportunities's 3-1 Month Momentum % is 10.05%.
The industry rank for RTW Biotech Opportunities's 3-1 Month Momentum % or its related term are showing as below:
LSE:RTW's 3-1 Month Momentum % is ranked better than 91.15% of 1627
companies
in the Asset Management industry
Industry Median: -0.35
vs LSE:RTW: 10.05
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
RTW Biotech Opportunities 3-1 Month Momentum % Related Terms
LSE:RTW vs BLK, BX, KKR: 3-1 Month Momentum % Comparison
For the Asset Management subindustry, RTW Biotech Opportunities's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RTW Biotech Opportunities 3-1 Month Momentum % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, RTW Biotech Opportunities's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where RTW Biotech Opportunities's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RTW Biotech Opportunities (LSE:RTW) has a 3-1 Month Momentum % of 10.05% as of Aug. 15, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on RTW Biotech Opportunities and its competitors. According to the industry distribution chart, RTW Biotech Opportunities ranks #144 out of 1627 companies in the Asset Management industry, placing it in the top 8.9%.
Is RTW Biotech Opportunities' 3-1 Month Momentum % too high?
RTW Biotech Opportunities' current 3-1 Month Momentum % is 10.05%. Based on the distribution chart, RTW Biotech Opportunities ranks #144 out of 1627 companies in the Asset Management industry, which is in the top quartile — a strong position relative to peers. Overall, RTW Biotech Opportunities has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' 3-1 Month Momentum % compare to BLK and BX?
According to the Asset Management industry distribution chart, RTW Biotech Opportunities ranks #144 out of 1627 companies for 3-1 Month Momentum %. This places RTW Biotech Opportunities in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for an Asset Management company?
A good 3-1 Month Momentum % depends on the Asset Management industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on RTW Biotech Opportunities and its competitors. RTW Biotech Opportunities's current 3-1 Month Momentum % is 10.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current 3-1 Month Momentum % of 10.05%. The current 3-1 Month Momentum % is 10.05%. RTW Biotech Opportunities' overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current 3-1 Month Momentum % is 10.05% as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
40GF Score
Get the complete analysis for LSE:RTW
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:RTW has been successfully added to your 
